Zoeken
Zoeken kan via de modus 'eenvoudig zoeken' (één veld) of uitgebreid via 'geavanceerd zoeken' (meerdere velden). Zo kan je bv. zoeken op een combinatie van een auteursnaam (auteur), een jaartal (jaar) en een documenttype.
Boekenmand
Nuttige resultaten kan je aanvinken en toevoegen aan een mandje. De inhoud hiervan kan je exporteren of afdrukken (naar bv. PDF).
RSS
Op de hoogte blijven van nieuw toegevoegde publicaties binnen uw interessegebied? Dit kan door een RSS-feed (?) te maken van jouw zoekopdracht.
nieuwe zoekopdracht
Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’
Cos, P.; Vlietinck, A.J.; Vanden Berghe, D.; Maes, L. (2006). Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’. Journal of Ethnopharmacology 106(3): 290-302. https://dx.doi.org/10.1016/j.jep.2006.04.003
In: Journal of Ethnopharmacology. Elsevier Science Ireland: Shannon. ISSN 0378-8741
|   |
| Author keywords |
Natural products; Antibacterial; Antifungal; Antiviral; Antiparasitic; Screening |
| Auteurs | | Top |
- Cos, P.
- Vlietinck, A.J.
- Vanden Berghe, D.
- Maes, L.
|
|
|
| Abstract |
Natural products, either as pure compounds or as standardized plant extracts, provide unlimited opportunities for new drug leads because of the unmatched availability of chemical diversity. To secure this, a number of pivotal quality standards need to be set at the level of extract processing and primary evaluation in pharmacological screening models. This review provides a number of recommendations that will help to define a more sound ‘proof-of-concept’ for antibacterial, antifungal, antiviral and antiparasitic potential in natural products. An integrated panel of pathogens is proposed for antimicrobial profiling, using accessible standard in vitro experimental procedures, endpoint parameters and efficacy criteria. Primary requirements include: (1) use of reference strains or fully characterized clinical isolates, (2) in vitro models on the whole organism and if possible cell-based, (3) evaluation of selectivity by parallel cytotoxicity testing and/or integrated profiling against unrelated micro-organisms, (4) adequately broad dose range, enabling dose–response curves, (5) stringent endpoint criteria with IC50-values generally below 100 μg/ml for extracts and below 25 μM for pure compounds, (6) proper preparation, storage and in-test processing of extracts, (7) inclusion of appropriate controls in each in vitro test replicate (blanks, infected and reference controls) and (8) follow-up of in vitro activity (‘hit’-status) in matching animal models (‘lead’-status). |
IMIS is ontwikkeld en wordt gehost door het VLIZ.
